Three DNA-PK related inhibitors MSC2490484A, CC-122, and CC-115 (DNA-PK and MTOR dual inhibitor) are currently being investigated in phase I clinical trial either for solid tumors, non-Hodgkin lymphoma, multiple myeloma or hematologic malignancies [33]. This evidence concerns the gene PRKDC and hematologic disorder.